Zituvimet Tablet, Film Coated
Product Images NDC 70771-1859

6 FDA label images from Zydus Lifesciences Limited · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Zituvimet (NDC 70771-1859). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Zydus Lifesciences Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structure (3bf9383a Afe0 4989 B952 50c995bd3fa5 01)

Structure (3bf9383a Afe0 4989 B952 50c995bd3fa5 01)
Chemical structure diagram of the active ingredient sitagliptin, displaying its molecular components including fluorine-substituted aromatic ring and trifluoromethyl group attached to a piperazine ring.*
FDA Label Image

Structure (3bf9383a Afe0 4989 B952 50c995bd3fa5 02)

Structure (3bf9383a Afe0 4989 B952 50c995bd3fa5 02)
Chemical structure of Sitagliptin Hydrochloride, the active ingredient in ZITUVIMET tablets, depicted with molecular bonds and chemical groups including methyl and amino groups along with hydrochloride (HCl).*
FDA Label Image

Graph (3bf9383a Afe0 4989 B952 50c995bd3fa5 03)

Graph (3bf9383a Afe0 4989 B952 50c995bd3fa5 03)
A line graph depicting LS mean change from baseline over 24 weeks for different treatment groups: Placebo, Metformin 1000 mg twice daily, Sitagliptin 100 mg once daily, Sitagliptin 50 mg twice daily, Sitagliptin 50 mg plus Metformin 500 mg twice daily, and Sitagliptin 50 mg plus Metformin 1000 mg twice daily. The y-axis shows LS mean change from baseline and the x-axis shows weeks from 0 to 24.*
FDA Label Image

Graph (3bf9383a Afe0 4989 B952 50c995bd3fa5 04)

Graph (3bf9383a Afe0 4989 B952 50c995bd3fa5 04)
A line graph comparing the least squares mean change from baseline over 52 weeks between Sitagliptin 100 mg and Glipizide. The y-axis represents the mean change from baseline, and the x-axis represents time in weeks. Both treatments show a decrease initially and stabilize over time with similar trends.*
FDA Label Image

Label (3bf9383a Afe0 4989 B952 50c995bd3fa5 05)

Label (3bf9383a Afe0 4989 B952 50c995bd3fa5 05)
Packaging label for ZITUVIMET 50 mg/500 mg film-coated tablets containing sitagliptin and metformin hydrochloride. The label shows the product name, strength, NDC 70771-1859-6, and quantity of 60 tablets. It includes dosage and storage instructions, manufacturer Zydus Lifesciences Ltd., Ahmedabad, India, and a barcode.*
FDA Label Image

Label (3bf9383a Afe0 4989 B952 50c995bd3fa5 06)

Label (3bf9383a Afe0 4989 B952 50c995bd3fa5 06)
The packaging label for ZITUVIMET tablets, containing sitagliptin 50 mg and metformin hydrochloride 1,000 mg. The label includes the NDC 70771-1860-6, indicates the product is a film-coated oral tablet, and lists a package size of 60 tablets. It also notes the manufacturer as Zydus Lifesciences Limited. Additional storage and usage instructions are included on the label.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.